ANTICIPATING TREATMENT NON-PERSISTENCE THROUGH AN INNOVATIVE CONCEPTUAL FRAMEWORK

Published Mar 7, 2015
Paderborn, Germany - Using principles from behavioral economics to model patient decisions, innovative research published in Value in Health proposes a framework to understand the reasons for treatment non-persistence and predicts the point at which a patient will stop taking their medication. This information could contribute to the development of tailored intervention solutions to ensure the patient stays on track and continues taking their medicine as prescribed. The conceptual model described in the article, “Conceptual Model and Economic Experiments to Explain Non-persistence and Enable Mechanism Designs Fostering Behavioral Change,” bridges the economic principles of loss aversion and mental accounting with health behavior. The model highlights that a point exists where a patient feels that they have been adequately compensated for their perceived losses, such as effort to travel to see their doctor, or loss of day at work because of ill health. It is at this point that they will stop taking their medicine and thus the benefit of persistence is no longer greater than non-persistence. “This research will equip health care professionals with a way to generate insights on patient persistence behaviors. The incorporation of this intelligence into existing strategies could lead to more sophisticated, personalized tools that work towards maintaining treatment compliance.” said co-author Prof. Dr. René Fahr, PhD, from the University of Paderborn in Paderborn, Germany. Whereas previous research has limitations in its focus solely on rational choice behavior or retrospective identification of correlations between behaviors and discontinuation, this conceptual model is prospective, scalable and can be calibrated. In practice, it may therefore result in better health outcomes for patients and a reduction in costs through more efficient health care delivery.

Related Stories

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×